Deflazacort (Deflazacort) Patent Expiration, LOE Window & CMS Spending

Deflazacort (Deflazacort) by Aurobindo Pharma: Multi-Source Generic Molecule, 12 AB generics, $21.7M 2024 CMS Part D & Medicaid spend, and $14,215 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAurobindo Pharma
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$21.7M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$20.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($14,215 intro WAC)